Pathios Secures $25M in Funding from BMS to Advance GPR65 Checkpoint Inhibitor Development
Pathios, Bristol-Myers Squibb (BMS), funding, GPR65, checkpoint inhibitor, cancer immunotherapy, drug development, biotechnology, investment.
Vertex Initiates FDA Rolling Review for Non-Opioid Pain Medication Suzetrigine (VX-548)
Vertex Pharmaceuticals, Suzetrigine (VX-548), Non-opioid painkiller, FDA rolling review, Acute pain
Metsera Emerges with $290M to Rival Obesity Pharmaceutical Giants Lilly and Novo
Metsera, $290M funding, Obesity treatment, Challenge Lilly and Novo, GLP-1 receptor agonist (Phase I injectable)
Cerevel Reports Phase 3 Parkinson’s Study Success Amidst AbbVie Acquisition
Cerevel Therapeutics, Phase 3 Parkinson’s disease trial, Tavapadon, AbbVie acquisition, Successful clinical trial results
Biotech Company Raises $54M to Dominate Dendritic Cell-Amplifying Vaccines Market
Biotech, $54M funding, Dendritic cell-amplifying vaccines, Market cornering, Immune response, Apex regulators
23andMe Stock Surges as CEO Considers Taking Company Private
23andMe, Stock Jump, CEO, Privatization Plans, Genetics Company
FDA Grants De Novo Clearance to Scopio Labs’ AI-Powered Bone Marrow Pathology Application for Blood Disorders and Cancer
Scopio Labs, De Novo Clearance, FDA, Bone Marrow Pathology, AI, Blood Disorders, Cancer
Charles River Launches Initiative for Animal Testing Alternatives
Charles River, Animal Testing Alternatives, Program Launch, Non-Animal Testing, Drug Development
Fujifilm Diosynth’s Restructuring Plan May Leave 240 Employees Jobless
Fujifilm Diosynth, CDMO (Contract Development and Manufacturing Organization), Restructuring plan, Potential job loss, 240 staffers
MedinCell and AbbVie Collaborate on Long-Acting Injectable Development with a Potential Value of $1.9 Billion
MedinCell, AbbVie, Long-acting injectable, Development pact, $1.9 billion